Reduction of Serum IGF-I Levels in Patients Affected with Monoclonal Gammopathies of Undetermined Significance or Multiple Myeloma. Comparison with BFGF, VEGF and K-ras Gene Mutation

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2009 Mar 17

PMID 19284554

Citations 6

Authors

Claudia Greco

Gaetano Vitelli

Giuseppe Vercillo

Rosa Vona

Diana Giannarelli

Isabella Sperduti

Francesco Pisani

Ettore Capoluongo

Maria Concetta Petti

Franco Ameglio

Affiliations

Soon will be listed here.

Abstract

Background: Serum levels of IGF-I in patients affected with multiple myeloma (MM) have been scarcely studied. The present study is aimed to explore this point comparing 55 healthy subjects, 71 monoclonal gammopaties of uncertain significance (MGUS) and 77 overt MM patients. In the same subjects, basic FGF and VEGF, have been detected. All three mediators were analyzed in function of K-ras mutation and melphalan response. Concerning IGF-I, two representative monitoring examples have also been added.

Methods: Cytokine determinations were performed by commercially available ELISA kits, while K12-ras mutation was investigated on genomic DNA isolated from bone marrow cell specimens by RFLP-PCR assay.

Results: Significant reductions of IGF-I levels were observed in MGUS and MM as compared with healthy controls. In addition, MM subjects showed significantly decreased serum IGF-I levels than MGUS. Conversely, increasing levels were observed for bFGF and VEGF, molecules significantly correlated. A multivariate analysis corrected for age and gender confirmed the significant difference only for IGF-I values (P = 0.01). K12-ras mutation was significantly associated with malignancy, response to therapy and with significantly increased serum bFGF levels.

Conclusion: IGF-I reduction in the transition: Controls-->MGUS-->MM and changes observed over time suggest that IGF-I should be furtherly studied in future clinical trials as a possible monitoring marker for MM.

Citing Articles

Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance.

Melaccio A, Reale A, Saltarella I, Desantis V, Lamanuzzi A, Cicco S J Clin Med. 2022; 11(21).

PMID: 36362718 PMC: 9658666. DOI: 10.3390/jcm11216491.

Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.

Allegra A, Innao V, Allegra A, Pugliese M, Di Salvo E, Ventura-Spagnolo E Int J Mol Sci. 2019; 20(11).

PMID: 31185596 PMC: 6600674. DOI: 10.3390/ijms20112822.

Pre-diagnostic blood immune markers, incidence and progression of B-cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses.

Vermeulen R, Hosnijeh F, Bodinier B, Portengen L, Liquet B, Garrido-Manriquez J Int J Cancer. 2018; 143(6):1335-1347.

PMID: 29667176 PMC: 6100111. DOI: 10.1002/ijc.31536.

The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential.

Bieghs L, Johnsen H, Maes K, Menu E, Van Valckenborgh E, Overgaard M Oncotarget. 2016; 7(30):48732-48752.

PMID: 27129151 PMC: 5217049. DOI: 10.18632/oncotarget.8982.

Lack of correlation between angiogenic cytokines and serum insulin-like growth factor-1 in patients with multiple myeloma.

Pappa C, Tsirakis G, Psarakis F, Kolovou A, Tsigaridaki M, Stafylaki D Med Oncol. 2012; 30(1):363.

PMID: 23266941 DOI: 10.1007/s12032-012-0363-0.

References

Clemmons D . Clinical utility of measurements of insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab. 2006; 2(8):436-46. DOI: 10.1038/ncpendmet0244. View

Hu L, Shi Y, Hsu J, Gera J, Van Ness B, Lichtenstein A . Downstream effectors of oncogenic ras in multiple myeloma cells. Blood. 2003; 101(8):3126-35. DOI: 10.1182/blood-2002-08-2640. View

Kumar S, Witzig T, Timm M, Haug J, Wellik L, Kimlinger T . Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood. 2004; 104(4):1159-65. DOI: 10.1182/blood-2003-11-3811. View

Zhong H, Phillip Bowen J . Antiangiogenesis drug design: multiple pathways targeting tumor vasculature. Curr Med Chem. 2006; 13(8):849-62. DOI: 10.2174/092986706776361085. View

Hrycek A, Gruszka A . Thyroid hormone and insulin-like growth factor-I in patients with multiple myeloma treated with melphalan and prednisone. Arch Med Res. 2005; 37(1):74-8. DOI: 10.1016/j.arcmed.2005.04.015. View

Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T . Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 1995; 55(20):4575-80. View

Goto F, Goto K, Weindel K, Folkman J . Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest. 1993; 69(5):508-17. View

Korc M . Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am. 1998; 7(1):25-41. View

Alexandrakis M, Passam F, Sfiridaki A, Pappa C, Moschandrea J, Kandidakis E . Serum levels of leptin in multiple myeloma patients and its relation to angiogenic and inflammatory cytokines. Int J Biol Markers. 2004; 19(1):52-7. DOI: 10.1177/172460080401900107. View

10.

Ghaneh P, Kawesha A, Evans J, Neoptolemos J . Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg. 2002; 9(1):1-11. DOI: 10.1007/s005340200000. View

11.

Ribas C, Colleoni G, Silva M, Carregoza M, Bordin J . Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma. Eur J Haematol. 2004; 73(5):311-7. DOI: 10.1111/j.1600-0609.2004.00314.x. View

12.

Chi S, Kitanaka C, Noguchi K, Mochizuki T, Nagashima Y, Shirouzu M . Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells. Oncogene. 1999; 18(13):2281-90. DOI: 10.1038/sj.onc.1202538. View

13.

Ikeda N, Nakajima Y, Sho M, Adachi M, Huang C, Iki K . The association of K-ras gene mutation and vascular endothelial growth factor gene expression in pancreatic carcinoma. Cancer. 2001; 92(3):488-99. DOI: 10.1002/1097-0142(20010801)92:3<488::aid-cncr1347>3.0.co;2-f. View

14.

Ge N, Rudikoff S . Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood. 2000; 96(8):2856-61. View

15.

Tucci A, Bonadonna S, Cattaneo C, Ungari M, Giustina A, Guiseppe R . Transformation of a MGUS to overt multiple myeloma: the possible role of a pituitary macroadenoma secreting high levels of insulin-like growth factor 1 (IGF-1). Leuk Lymphoma. 2003; 44(3):543-5. DOI: 10.1080/1042819021000037895. View

16.

Ria R, Vacca A, Russo F, Cirulli T, Massaia M, Tosi P . A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. Thromb Haemost. 2004; 92(6):1438-45. DOI: 10.1160/TH04-06-0334. View

17.

Larsson O, Girnita A, Girnita L . Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer. 2005; 92(12):2097-101. PMC: 2361813. DOI: 10.1038/sj.bjc.6602627. View

18.

Vacca A, Ribatti D . Bone marrow angiogenesis in multiple myeloma. Leukemia. 2005; 20(2):193-9. DOI: 10.1038/sj.leu.2404067. View

19.

Molica S, Vitelli G, Mirabelli R, Digiesu G, Giannarelli D, Cuneo A . Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression. Eur J Haematol. 2005; 76(1):51-7. DOI: 10.1111/j.1600-0609.2005.00553.x. View

20.

Bellamy W . Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin Oncol. 2001; 28(6):551-9. DOI: 10.1016/s0093-7754(01)90023-5. View